ZEPOSIA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Estonia, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, UK.

Active ingredients

The drug ZEPOSIA contains one active pharmaceutical ingredient (API):

1	Ozanimod UNII 3UPR33JAAM - OZANIMOD HYDROCHLORIDE
	Ozanimod is a potent sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity to sphingosine 1-phosphate receptors 1 and 5. Ozanimod has minimal or no activity on S1P~2, S1P3, and S1P4. In vitro, ozanimod and its major active metabolites demonstrated similar activity and selectivity for S1P1 and S1P5. The mechanism by which ozanimod exerts therapeutic effects in MS and UC is unknown, but may involve the reduction of lymphocyte migration into the central nervous system (CNS) and intestine.
	Read more about Ozanimod

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZEPOSIA Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)
ZEPOSIA Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AE02		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AE Sphingosine-1-phosphate (S1P) receptor modulators
Discover more medicines within L04AE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	12271W, 12278F
CA	Health Products and Food Branch	02505991, 02506009
EE	Ravimiamet	1820854, 1820876, 1820966
FR	Base de données publique des médicaments	62377435, 69203387
GB	Medicines & Healthcare Products Regulatory Agency	391303, 391306, 391309, 391312
HK	Department of Health Drug Office	67126, 67127
IE	Health Products Regulatory Authority	89088, 89089
IL	מִשְׂרַד הַבְּרִיאוּת	8798, 8799, 8800
IT	Agenzia del Farmaco	048818013, 048818025, 048818037
LT	Valstybinė vaistų kontrolės tarnyba	1090323, 1090324, 1090325
NL	Z-Index G-Standaard, PRK	203939, 203947
NZ	Medicines and Medical Devices Safety Authority	22323, 22324
PL	Rejestru Produktów Leczniczych	100438934, 100438940
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67064001, W67065001, W67065002
US	FDA, National Drug Code	59572-820